BioCardia, Inc.
Biological Products, (No Diagnostic Substances) · SUNNYVALE · CA
Moderate confidence (50%)
Updated Oct 4, 2026, 12:04 AM
What is happening
Derived by rule set status-rules-2026.09.7
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
Latest material event: BioCardia, Inc. received a delisting notice from its exchange (Aug 19, 2026)
Timeline
Every material event, newest first. History is never overwritten.
BioCardia, Inc. received a delisting notice from its exchange
Aug 19, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On August 19, 2026, BioCardia, Inc. (the Company ) received a written notice (the Notice ) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC ( Nasdaq ) indicating that, for the last 30 consecutive business days, the minimum bid price of the Company s common stock had been below the $1.00 per share minimum requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement ). In accordance with…”
BioCardia, Inc. received a delisting notice from its exchange
Jun 12, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed on that certain Current Report on Form 8-K filed with the Securities and Exchange Commission (the SEC ) on April 15, 2026 (the Original 8-K ), on April 10, 2026, BioCardia, Inc. (the Company, we, us and our ) received a notification letter (the Notice ) from the Nasdaq Listing Qualifications Staff (the Staff ) of The Nasdaq Stock Market LLC ( Nasdaq ) notifying the Company that its amount of stockholders equity had fallen below the $2,500,000 required minimum…”
BioCardia, Inc. received a delisting notice from its exchange
Apr 10, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 10, 2026, BioCardia, Inc. (the Company ) received written notice (the Notice ) from The Nasdaq Stock Market LLC ( Nasdaq ) notifying the Company that, based on the Company s stockholders equity of $895,000 as of December 31, 2025, it is no longer in compliance with the minimum stockholders equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1). The Company has until May 25, 2026 to provide Nasdaq with a plan…”
Company information
- Founded
- —
- Employees (estimate)
- —
- Industry
- Biological Products, (No Diagnostic Substances)
- Subindustry
- —
- Listing
- SEC lists the ticker BCDA on Nasdaq.
- SEC CIK
- 0000925741
- Website
- —
- —
- Headquarters
- SUNNYVALE, CA
- Also known as
- Cardo Medical, Inc., CLICKNSETTLE COM INC, NAM CORP, Tiger X Medical, Inc.
- Legal entities
- BioCardia, Inc.
Sources
Every material source used to build this profile.
SEC Company Submissions (TIER 1 · UNVERIFIED)
BioCardia, Inc. — Biological Products, (No Diagnostic Substances) (SIC 2836) — SUNNYVALE, CA
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 10, 2026, BioCardia, Inc. (the Company ) received written notice (the Notice ) from The Nasdaq Stock Market LLC ( Nasdaq ) notifying the Company that, based on the Company s stockholders equity of $895,000 as of December 31, 2025, it is no longer in compliance with the minimum stockholders equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1). The Company has until May 25, 2026 to provide Nasdaq with a plan…
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On August 19, 2026, BioCardia, Inc. (the Company ) received a written notice (the Notice ) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC ( Nasdaq ) indicating that, for the last 30 consecutive business days, the minimum bid price of the Company s common stock had been below the $1.00 per share minimum requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement ). In accordance with…
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed on that certain Current Report on Form 8-K filed with the Securities and Exchange Commission (the SEC ) on April 15, 2026 (the Original 8-K ), on April 10, 2026, BioCardia, Inc. (the Company, we, us and our ) received a notification letter (the Notice ) from the Nasdaq Listing Qualifications Staff (the Staff ) of The Nasdaq Stock Market LLC ( Nasdaq ) notifying the Company that its amount of stockholders equity had fallen below the $2,500,000 required minimum…
View source record
Status history
Every derived status, with the rule that produced it.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:28 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:14 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:35 PM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 14, 2026, 12:01 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 03:12 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.